mGlu2 NAM Program for Addiction

About Camino Pharma

Camino Pharma is a private, preclinical-stage biotech company pioneering novel allosteric modulators for oncology and neuropsychiatric disorders. Its core expertise lies in targeting historically difficult protein classes like PTPs and GPCRs, with programs in cancer signaling, addiction, and treatment-resistant depression. The company is led by a seasoned founder-CEO with a track record of venture fundraising and drug development, and it maintains strong academic ties with the Sanford Burnham Prebys Medical Discovery Institute. While still pre-revenue, it has secured non-dilutive grant funding from the National Institute on Drug Abuse (NIDA) for its addiction program.

Therapeutic Areas

Other Addiction Drugs